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Abstract 
Study have been carried out on white Wistar line rats (age – 3 months, weight –  
180-220 g). According to the tasks the animals were divided into 7 groups. 1st group is intact  
(n = 20). 2nd group is rats, which were modeled osteoarthritis without further correction and 
were withdrawn from the experiment in the first stage (7th day) (n=40). 3rd group is rats, 
which were modeled osteoarthritis without further correction and removed from the 
experiment in the second stage (21st day) (n=40). 4th group is rats, in which experimental 
osteoarthritis was corrected with nonsteroidal anti-inflammatory drugs (NSAIDs) 
(Diclofenac) and aminoguanidine and removed from the experiment in the first stage (7th 
day) (n=20). 5th group is rats, in which experimental osteoarthritis was corrected with 
NSAIDs (Diclofenac) and aminoguanidine and withdrawn from the experiment in the second 
stage (21st day) (n=20). 6th group is rats, where experimental osteoarthritis was corrected 
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using NSAIDs and a 7% L-arginine solution and withdrawn from the experiment in the first 
stage (7th day) (n=20). 7th group is rats, in which experimental osteoarthritis was corrected 
with NSAIDs and 7% L-arginine solution and withdrawn from the experiment in the second 
stage (21st day) (n=20) 
Animals were withdrawn from the experiment for the 7th day and the 21st day after 
the simulation of the pathological condition. NSAIDs (Diclofenac), aminoguanidine and L-
arginine were administered from the beginning of the study. 
We have obtained the following results: 
The increase in the content of von Willebrand factor (VWF) in the animals blood 
proves that endothelial dysfunction is an important part of experimental osteoarthritis 
pathogenesis. It’s revealed the tendency which directed on normalization of the endothelial 
dysfunction investigated marker at correction by aminoguadine as a part of complex therapy. 
L-arginine involvement in the complex correction in experimental osteoarthrit is more 
pronouncedly normalized the VWF level, which indicates the endothelial function 
normalization. The use of nitric oxide donor is more effective in comparison with the 
inhibition of inducible NO synthase also in the endothelial nitric oxide synthase activity 
analysis. 
Key words: osteoarthritis; experimental model; endothelial dysfunction; Von 
Willebrand factor; endothelial NO synthase; aminoguanidine; L-arginine. 
 
Introduction. Osteoarthritis (OA) is considered as a complex disease in which all 
structural components of the joint are involved in the process [1, 2]. Several authors define 
OA as a heterogeneous diseases group of different etiology with identical clinical, 
morphological and biological manifestations, which are based on cartilage, subchondral bone, 
synovial membrane, ligament, capsule and paraartiular muscle damage [3, 4]. Recently, 
attention has been paid to endothelial pathology development  in patients with OA [5]. 
Significant role in this aspect is given to chronic inflammation, as endothelial dysfunction 
trigger mechanism.   
Oxidative stress [6, 7], endothelins production and endoperoxides, which are 
vasoconstrictors, are defined as causes of violation the functioning and endothelial vessels 
layer structure violation in osteoarthritis. Inflammatory cytokines that violate nitric oxide 




Materials and methods  
Study have been carried out on white Wistar line rats (age – 3 months, weight – 180-
220 g). According to the tasks the animals were divided into 7 groups:  
1st group is intact (n = 20). 
2nd group is rats, which were modeled osteoarthritis without further correction and 
were withdrawn from the experiment in the first stage (7th day) (n=40).  
3rd group is rats, which were modeled osteoarthritis without further correction and 
removed from the experiment in the second stage (21st day) (n=40).  
4th group is rats, in which experimental osteoarthritis was corrected with nonsteroidal 
anti-inflammatory drugs (NSAIDs) (Diclofenac) and aminoguanidine and removed from the 
experiment in the first stage (7th day) (n=20) 
5th group is rats, in which experimental osteoarthritis was corrected with NSAIDs 
(Diclofenac) and aminoguanidine and withdrawn from the experiment in the second stage 
(21st day) (n=20) 
6th group is rats, where experimental osteoarthritis was corrected using NSAIDs and a 
7% L-arginine solution and withdrawn from the experiment in the first stage (7th day) (n=20) 
7th group is rats, in which experimental osteoarthritis was corrected with NSAIDs and 
7% L-arginine solution and withdrawn from the experiment in the second stage (21st day) 
(n=20) 
Animals were withdrawn from the experiment for the 7th day and the 21st day after 
the simulation of the pathological condition. NSAIDs (diclofenac), aminoguanidine and L-
arginine were administered from the beginning of the study. 
Blood samples were taken for the biochemical study of the following parameters: 
Determination of  endothelial synthase activity was performed by spectrophotometric 
method [9, 10]. 
Aminoguadine is a selective inhibitor of inducible NO synthase (iNO-synthase), given 
to experimental animals at a dose of 15 mg/kg/day in the form of a solution in the free drink 
mode [11]. 
Nitric oxide donor administration a solution of L-arginine (SIMESTA, made in China, 
quality standard USP32) was carried out by intragastric injection of L-arginine solution in 
0.9% sodium chloride solution at a dose of 500 mg/kg (Pokrovsky M.V., Pokrovskaya T.G., 
Korchakov V.I., etc., 2008) through a syringe with a feeding tube. 
Both drugs were administered throughout the experiment. 
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Research was conducted in accordance with the "Rules for carrying out works using 
experimental animals", approved by the Order of the Ministry of Health of Ukraine No. 249 
of 01.03.2012 and the Law of Ukraine No. 3447-IV "On the Protection of Animals from Cruel 
Treatment" (as amended on December 15, 2009, and 10/16/2012) 
Destructive-dystrophic process of cartilage tissue was modeled by knee joint 
criodamadge. One-time intraarticular injection was performed with  solution of cooled ethanol 
(Vedensky B.P., Galchenko S.E., Kovalev G.O., 2011).  
Choice of this modeling method is justified by the fact that it does not require surgery, 
allows to standardize the experimental reproduction of the pathological process, reduces the 
risk of complications and does not lead to paraarticular tissues damage. This model provides a 
high frequency of consequences of local and general changes in the body in response to a 
modeled pathological process [12]. 
Before using parametric, normality-based statistical distribution methods, it were used 
to test the series of quantitative data for normality using the Shapiro–Wilk test. Due to the 
normal distribution of digital data in the samples, was used  Student's parametric criterion. 
Research results  
Based on obtained results, we can assert that endothelial dysfunction develops on the 
background of a modeled osteoarthritis: established increasing of von Willebrand factor 
(VWF), which is a commonly used endothelial dysfunction (ED) markers. (Table 1).  
 
Table 1. Von Willebrand factor levels' dynamic in the rats blood  during experimental 
osteoarthritis and its correction 
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At the first research stage, an increase indicator content in experimental animals blood 
of 2nd group was found to be 13.9% compared with the data of intact animals. At the second 
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stage, differences between first group and rats results that weren’t correct for the modified 
osteoarthritis were 11.6%, which indicates that the adaptive properties of the organism are 
insignificant for the restoration of the functional state of the endothelium (differences between 




















Figure 1 – Dynamics of VWF in the first stage of the experiment 
 
The level' dynamics ED studied marker at the first stage of the experiment is presented 
in Fig. 1. 
Aminoguanidine effectiveness review' s in combination with NSAIDs, it was found 
that in the first stage, its level decreased with respect to animals groups data without 
correction by 3.9%, and in the second - by 2.4%, that is, there no pronounced positive 
inducible NO- syntase inhibitor effect for endothelium functional state marker normalization. 
Results of the study groups that modeled OA corrected using NSAIDs and L-arginine, was 
found Von Willebrand factor improvement to be 8.9% in the first stage and 9.5% in the 
second (differences in both cases is with statistic significant at p <0.001) (Table 1). Foregoing 
indicates that use of L-arginine is more appropriate for endothelial dysfunction correction in 
experimental osteoarthritis. 






























Figure 2 – Dynamics of VWF in the second stage of the experiment  
 
According to the literature, it is known that the link between increased VWF 
concentration in the blood with the vascular endothelial degree exposure has been repeatedly 
proven in a number of model experiments in rats with endotoxemia and mechanical 
endothelial damage [13-15], as well as in a number of clinical observations. [16]. 
Von Willebrand factor is synthesized by endothelial cells and circulates in blood 
plasma at a concentration of about 10 pg/ml [16]. The most significant role of VWF is the 
mediator function in the vascular-platelet interaction at the adhesion stages, platelet 
aggregation [17, 18]. In these reactions, VWF acts as a bridge between the subendothelial 
structures of the damaged vascular wall and platelets, as well as between individual platelets 
[19].  
It is also known that VWF is synthesized with a certain "stock", VWF molecules that 
do not participate in the implementation of physiological functions accumulate in the 
endothelial cells' intracellular organelles - Weibel-Palade bodies, where they are subject to 













Nitric oxide endothelial synthase dynamics in rats blood at experimental osteoarthritis 
and its correction.  
It was found that the endothelial functional status violation correction by inhibitor of 
iNOS only restored the endothelial nitric oxide synthase activity in the first stage (group 4) 
and by 11.7% in the second group (group 5) by 6.5% compared to the results animals of 
group №2. 
Correction of the pathological state by means of the involvement of L-arginine in the 
complex therapy gave a more pronounced effect (Figure 3): in the first stage, the activity of 
the eNOS increased by 33.7% compared with the data of group number 2, and in the second 
stage - by 63.1% (also in comparison with a group of rats, to which the pathological state was 





















Figure 3 – Dynamics of endothelial NO syntase  in the first stage of the experiment 
 
That is, in the first stage, the correction with a NSAIDs and a nitric oxide donor 
restored the activity of eNOS to 25.5% better, and in the second stage - by 46% better than the 
group's results, which was corrected by NAIDs and an inhibitor of NO synthase inhibitor. It 
should be noted that the effectiveness of the effect of L-arginine on the course of the 
pathological process increases with the duration of its use in the experimental OA: the effect 






1st stage  
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Figure 4 – Dynamics of endothelial NO syntase  in the second stage of the experiment 
 
Conclusions 
1. The increase in the content of von Willebrand factor (VWF)  in the animals 
blood proves that endothelial dysfunction is an important part of experimental osteoarthritis 
pathogenesis. 
2. It’s revealed the tendency which directed on normalization of the  endothelial 
dysfunction investigated marker at correction by aminoguadine as a part of complex therapy. 
3. L-arginine involvement in the complex correction in experimental 
osteoarthritis more pronouncedly normalized the VWF level, which indicates the endothelial 
function normalization.  
4. The use of nitric oxide donor is more effective in comparison with the 
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